Authors: Hussein Ghanem, Adham Zaazaa, Gamal Soltan, Hossam Hosny Awad, Osama Selim
Abstract: The neurobiological approach to life-long premature ejaculation (PE) has shed new light on selective serotonin reuptake inhibitors as a main and first line of treatment. Escitalopram, being one of the most prominent selective serotonin reuptake inhibitors, has been used in this study. Aim: To assess the effect of a daily dosage of escitalopram on ejaculatory latency in patients diagnosed as having definite PE, as well as to assess the side effects of the drugs during the treatment period. Methods: Patients were blindly randomized to receive placebo tablets once daily for 4 weeks or escitalopram 10 mg/day for 4 weeks. (Cipralex; H. Lundbeck A/S, Denmark). Intravaginal ejaculatory latency time (IELT) was measured using a stopwatch in the two groups at 2 and 4 weeks of treatment. Side effects of the drug were recorded in the two groups at 2 and 4 weeks of treatment. Results: In the group receiving the drug, there was a 226% IELT increase after 2 weeks of treatment and a 503% IELT increase after 4 weeks. After 2 weeks, significant side effects were recorded in the group receiving escitalopram, but these side effects decreased after 4 weeks of drug intake to become statistically insignificant. Conclusion: Treatment of patients with definite PE with a daily dose of escitalopram 10 mg/day resulted in a delay in ejaculation measured by IELT. Side effects of the drug that arose during therapy decreased gradually to become insignificant at 4 weeks of treatment.
Abstract: The neurobiological approach to life-long premature ejaculation (PE) has shed new light on selective serotonin reuptake inhibitors as a main and first line of treatment. Escitalopram, being one of the most prominent selective serotonin reuptake inhibitors, has been used in this study. Aim: To assess the effect of a daily dosage of escitalopram on ejaculatory latency in patients diagnosed as having definite PE, as well as to assess the side effects of the drugs during the treatment period. Methods: Patients were blindly randomized to receive placebo tablets once daily for 4 weeks or escitalopram 10 mg/day for 4 weeks. (Cipralex; H. Lundbeck A/S, Denmark). Intravaginal ejaculatory latency time (IELT) was measured using a stopwatch in the two groups at 2 and 4 weeks of treatment. Side effects of the drug were recorded in the two groups at 2 and 4 weeks of treatment. Results: In the group receiving the drug, there was a 226% IELT increase after 2 weeks of treatment and a 503% IELT increase after 4 weeks. After 2 weeks, significant side effects were recorded in the group receiving escitalopram, but these side effects decreased after 4 weeks of drug intake to become statistically insignificant. Conclusion: Treatment of patients with definite PE with a daily dose of escitalopram 10 mg/day resulted in a delay in ejaculation measured by IELT. Side effects of the drug that arose during therapy decreased gradually to become insignificant at 4 weeks of treatment.
0 comments:
Post a Comment